Drinking Matcha green tea (MGT) could stop the spread of breast cancer stem cells, according to new, ground-breaking medical research.
The study carried out by scientists at the Biomedical Research Centre at Salford University has shown, for the first time, that MGT can inhibit the spread of breast cancer cells.
It strongly proposes that the MGT natural compound can help overcome cancer cell resistance to chemotherapy.
The study subsequently concluded that treatment of the cells with MGT ‘shifted cancer cells towards a more quiescent metabolic state’ (essentially preventing the cancer cells from ‘refuelling’), and ‘that MGT effectively inhibits the propagation of cancer stem cells’.
The research has been driven by Katherine Swift, who is the founder of matcha tea company OMGTea.
When Katherine’s mother was in 2010 diagnosed with stage 3 breast cancer, she wanted to do something to support her through the treatment.
At the same time, she was involved in a high-profile fundraising campaign for Breakthrough Breast Cancer and became involved in supporting the ground-breaking research of Professor Michael Lisanti, who is said to be one of the world’s leading genetic and cell biologists. The research highlighted the positive effects of antioxidants in our diets.
Inspired by the research, Katherine discovered matcha, which she and her mum started drinking. Katherine felt so passionate about it, she founded OMGTea.
The new research findings follow Katherine’s appearance on BBC1’s Food: Truth or Scare last Friday, during which she discussed her mum’s story and the impact she believes MGT had on her recovery.
“I genuinely believe MGT played a part in my mum’s recovery, along with everything else that she did, and part of that is probably to do with the psychological boost she got from taking a bit of control herself,” says Katherine.
The research outcomes, which were observed with the concentration of MGT in the studies matching the concentration of a regular cup of MGT (0.2mg/ml), also raised the possibility that MGT could be used in place of chemical drugs such as rapamycin.
The research was subsequently published in peer-reviewed journal Aging.
Following the outcomes of the study, the team of researchers from Salford University are undertaking further research on the anti-cancerous effects of MGT, including clinical trials.
“Whilst this is still very early stage research, and we are by no means claiming that MGT can ‘cure’ cancer, the scientific outcomes do show that MGT has the potential to inhibit the spread of breast cancer stem cells, says Katherine.
“This is a hugely exciting development, and with further research we aim to discover more about the possible benefits of MGT in fighting cancer cells.”